MEG3 and thyroid cancer: In colorectal cancer, non-small cell lung cancer, thyroid cancer, and acute myeloid leukemia, MEG3 was found to have a high expression in the treatment-sensitive group and to combine the relevant microRNAs to improve therapy sensitivity (31–34).